Filtrer vos résultats
- 2
- 1
- 3
- 3
- 1
- 1
- 1
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALMJournal of Crohn's and Colitis, 2019, 13 (1), pp.S24-S25. ⟨10.1093/ecco-jcc/jjy222.032⟩
Article dans une revue
hal-03552307v1
|
|||
|
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialThe Lancet Gastroenterology & Hepatology, 2023, 8 (3), pp.215-227. ⟨10.1016/S2468-1253(22)00385-5⟩
Article dans une revue
hal-03947192v1
|
||
CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease: Data from the CALM studyJournal of Crohn's and Colitis, 2020, 14 (1), pp.S264-S266
Article dans une revue
hal-03551541v1
|